Treatment Resistant Depression: Strategies for Primary Care

被引:19
作者
Preston, Taylor C. [1 ]
Shelton, Richard C. [1 ]
机构
[1] Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA
关键词
Depression; Antidepressants; Treatment-resistant depression; Augmentation; Combination therapy; Antidepressant switch; Complementary and alternative therapy; Psychotherapy; Psychiatry; Primary care; STAR-ASTERISK-D; SEROTONIN REUPTAKE INHIBITORS; DOUBLE-BLIND; ANTIDEPRESSANT AUGMENTATION; DISORDER; THERAPY; LITHIUM; NONRESPONDERS; OUTCOMES; TRIAL;
D O I
10.1007/s11920-013-0370-7
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Depression is commonly diagnosed and treated in primary care. Recent evidence indicates that the majority of depressed patients will not fully recover with an initial antidepressant treatment. This paper reviews commonly used options for treatment after an inadequate initial antidepressant response. The alternatives range widely, and include escalating the dose of the initial antidepressant, switching to an alternative medication, combining two antidepressants with different mechanisms of action (e.g., bupropion + SSRI or mirtazapine + venlafaxine), adding other medications such as lithium or certain atypical antipsychotics (olanzapine, aripiprazole, or quetiapine) to the antidepressant, adding a natural product such as l-methylfolate or s-adenosylmethionine (SAMe), or adding cognitive behavioral psychotherapy. What agent to be used will depend on the comfort level of the primary care practitioner and the availability of Psychiatry referral. However, it is reasonable to take one or more additional steps to attempt to achieve remission.
引用
收藏
页数:6
相关论文
共 32 条
[1]   S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder -: An open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine [J].
Alpert, JE ;
Papakostas, G ;
Mischoulon, D ;
Worthington, JJ ;
Petersen, T ;
Mahal, Y ;
Burns, A ;
Bottiglieri, T ;
Nierenberg, AA ;
Fava, M .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2004, 24 (06) :661-664
[2]   Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines [J].
Anderson, I. M. ;
Ferrier, I. N. ;
Baldwin, R. C. ;
Cowen, P. J. ;
Howard, L. ;
Lewis, G. ;
Matthews, K. ;
McAllister-Williams, R. H. ;
Peveler, R. C. ;
Scott, J. ;
Tylee, A. .
JOURNAL OF PSYCHOPHARMACOLOGY, 2008, 22 (04) :343-396
[3]   Lithium augmentation therapy in refractory depression -: Update 2002 [J].
Bauer, M ;
Forsthoff, A ;
Baethge, C ;
Adli, M ;
Berghöfer, A ;
Döpfmer, S ;
Bschor, T .
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2003, 253 (03) :132-139
[4]   A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: A clinical, pharmacokinetic, and pharmacogenetic investigation [J].
Baumann, P ;
Nil, R ;
Souche, A ;
Montaldi, S ;
Baettig, D ;
Lambert, S ;
Uehlinger, C ;
Kasas, A ;
Amey, M ;
JonzierPerey, M .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1996, 16 (04) :307-314
[5]   Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder [J].
Gentile, Salvatore .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2007, 27 (01) :35-45
[6]   A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine [J].
Carpenter, LL ;
Yasmin, S ;
Price, LH .
BIOLOGICAL PSYCHIATRY, 2002, 51 (02) :183-188
[7]   If at First You Don't Succeed A Review of the Evidence for Antidepressant Augmentation, Combination and Switching Strategies [J].
Connolly, K. Ryan ;
Thase, Michael E. .
DRUGS, 2011, 71 (01) :43-64
[8]   Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies [J].
Correll, CU ;
Leucht, S ;
Kane, JM .
AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (03) :414-425
[9]   A placebo controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline [J].
Croft, H ;
Settle, E ;
Houser, T ;
Batey, SR ;
Donahue, RMJ ;
Ascher, JA .
CLINICAL THERAPEUTICS, 1999, 21 (04) :643-658
[10]   A prospective trial of bupropion SR augmentation of partial and non-responders to Serotonergic antidepressants [J].
DeBattista, C ;
Solvason, HB ;
Poirier, J ;
Kendrick, E ;
Schatzberg, AF .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (01) :27-30